Costimulatory signals, in addition to the T cell receptor engagement, are required for the optimal activation and survival of T lymphocytes. Lack of costimulatory activity may be responsible for immunological unresponsiveness to cancer. The overall goal of this study is to characterize cellular and molecular mechanisms of tumor immunity elicited by the costimulatory molecule 4-1BB (CDw137) and its ligand(4-1BBL). 4-1BBL belongs to the tumor necrosis factor (TNF) TNF receptor superfamily and are expressed primarily on activated T cells and antigen-presenting cells, respectively. The interaction of 4-1BB and 4-1BBL has been implicated in the costimulation of T cells. To this end, they have established mouse models in which engagement of 4-1BB by specific monoclonal antibodies induces immune responses leading to eradication of established large tumors. The primary effector cells for the immunity are CD4+, CD8+ T cells and natural killer (NK) cells. The central hypothesis of this proposal is that the 4-1BB pathway is required for the amplication of an ongoing immune response and lack of 4-1BB costimulation disrupts the process of tumor immunity. To test this hypothesis, they will examine the expression of 4-1BB on CD4+, CD8' T cells and NK cells during the early stage of tumor growth and identify the effector functions of key cellular components and cytokines in tumor immunity after direct 4-1BB ligation. In addition, they will explore the interaction between 4-1BB and B7-CD28 costimulatory pathways in order to enhance the activation of T cells and in antigen-presenting cells by transgenic techology can prevent the de novo development of cancer. It is anticipated that these studies will provide a foundation for the development of new approaches for the prevention and immunotherapy of cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA079915-03
Application #
6329063
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Mccarthy, Susan A
Project Start
1998-12-15
Project End
2002-11-30
Budget Start
2000-12-01
Budget End
2001-11-30
Support Year
3
Fiscal Year
2001
Total Cost
$228,969
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Zhu, Yuwen; Yao, Sheng; Chen, Lieping (2011) Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34:466-78
Lin, Pei-Yi; Sun, Lishi; Thibodeaux, Suzanne R et al. (2010) B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 185:2747-53
Hirano, Fumiya; Kaneko, Katsumi; Tamura, Hideto et al. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:1089-96
Vassallo, Robert; Chen, Lieping (2004) Selective suppression of dendritic cell functions by cigarette smoke extract. Chest 125:107S
Mukherjee, Pinku; Tinder, Teresa L; Basu, Gargi D et al. (2004) Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. Breast Dis 20:53-63
Wilcox, Ryan A; Tamada, Koji; Flies, Dallas B et al. (2004) Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 103:177-84
Weinman, Eric C; Roche, Patrick C; Kasperbauer, Jan L et al. (2003) Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer 97:2203-11
Kurosawa, Shin; Myers, Allen C; Chen, Lieping et al. (2003) Expression of the costimulatory molecule B7-H2 (inducible costimulator ligand) by human airway epithelial cells. Am J Respir Cell Mol Biol 28:563-73
Morris, Gerald P; Chen, Lieping; Kong, Yi-chi M (2003) CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol 226:20-9
Wilcox, Ryan A; Tamada, Koji; Strome, Scott E et al. (2002) Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169:4230-6

Showing the most recent 10 out of 23 publications